12.050USD+12.050After-hours 08/03, 20:00 (ET)
1.09BMarket Cap
LossP/E TTM
Key Figures
11.900Open
11.960High
516.78KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.63%Turnover Ratio
11.980Prev. Close
11.410Low
4.39MTurnover
LossP/E Static
-16.52P/B
0.00%Div Yield TTM
-51.44%ROA
11.85052wk High
1.02Volume Ratio
-147.79MNet Profit
81.45MShares
-1.4836EPS TTM
1.24Beta
-368.19%ROE
5.02052wk Low
4.59%Amplitude
32.42%Gross Margin
1.09BMarket Cap
-4.10Reward/Risk
3.35%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
MeiraGTx Holdings PLC's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 50 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MeiraGTx Holdings PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
MeiraGTx Holdings PLC Highlights
StrengthsRisks
MeiraGTx Holdings PLC News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
MeiraGTx Holdings PLC
MGTX
7
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MeiraGTx Holdings PLC Info
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Ticker SymbolMGTX
CompanyMeiraGTx Holdings PLC
CEOForbes (Alexandria)
Websitehttps://meiragtx.com/
Shareholders
FAQs
What is the current price of MeiraGTx Holdings PLC (MGTX)?
The current price of MeiraGTx Holdings PLC (MGTX) is 11.79.
What is the symbol of MeiraGTx Holdings PLC?
The ticker symbol of MeiraGTx Holdings PLC is MGTX.
What is the 52-week high of MeiraGTx Holdings PLC?
The 52-week high of MeiraGTx Holdings PLC is 11.85.
What is the 52-week low of MeiraGTx Holdings PLC?
The 52-week low of MeiraGTx Holdings PLC is 5.02.
What is the market capitalization of MeiraGTx Holdings PLC?
The market capitalization of MeiraGTx Holdings PLC is 1.09B.
Is MeiraGTx Holdings PLC (MGTX) currently rated as Buy, Hold, or Sell?
According to analysts, MeiraGTx Holdings PLC (MGTX) has an overall rating of Buy, with a price target of 29.29.
What is the Earnings Per Share (EPS TTM) of MeiraGTx Holdings PLC (MGTX)?
The Earnings Per Share (EPS TTM) of MeiraGTx Holdings PLC (MGTX) is -1.42.
